LUC00045I2 - - Google Patents

Download PDF

Info

Publication number
LUC00045I2
LUC00045I2 LU00045C LUC00045C LUC00045I2 LU C00045 I2 LUC00045 I2 LU C00045I2 LU 00045 C LU00045 C LU 00045C LU C00045 C LUC00045 C LU C00045C LU C00045 I2 LUC00045 I2 LU C00045I2
Authority
LU
Luxembourg
Application number
LU00045C
Original Assignee
Roche Glycart Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41351729&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LUC00045(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Roche Glycart Ag filed Critical Roche Glycart Ag
Publication of LUC00045I1 publication Critical patent/LUC00045I1/fr
Publication of LUC00045I2 publication Critical patent/LUC00045I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
LU00045C 2009-08-14 2017-10-26 LUC00045I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09010489 2009-08-14
PCT/EP2010/004939 WO2011018224A1 (fr) 2009-08-14 2010-08-12 Polythérapie à base d'un anticorps afucosylé anti-cd20 et de bendamustine
EP10747168.2A EP2464382B1 (fr) 2009-08-14 2010-08-12 Thérapie combinée d'un anticorps cd20 afucosylaté et de bendamustine

Publications (2)

Publication Number Publication Date
LUC00045I1 LUC00045I1 (fr) 2017-11-03
LUC00045I2 true LUC00045I2 (fr) 2018-02-26

Family

ID=41351729

Family Applications (1)

Application Number Title Priority Date Filing Date
LU00045C LUC00045I2 (fr) 2009-08-14 2017-10-26

Country Status (34)

Country Link
US (4) US20110165151A1 (fr)
EP (1) EP2464382B1 (fr)
JP (3) JP5646626B2 (fr)
KR (1) KR101425736B1 (fr)
CN (2) CN107261138A (fr)
AR (1) AR077866A1 (fr)
AU (1) AU2010281866B2 (fr)
CA (1) CA2769674C (fr)
CL (1) CL2012000391A1 (fr)
CR (1) CR20120036A (fr)
CY (2) CY1119251T1 (fr)
DK (1) DK2464382T3 (fr)
ES (1) ES2630158T3 (fr)
HK (1) HK1245145A1 (fr)
HR (1) HRP20170972T1 (fr)
HU (2) HUE033531T2 (fr)
IL (1) IL217753A (fr)
LT (2) LT2464382T (fr)
LU (1) LUC00045I2 (fr)
MA (1) MA33469B1 (fr)
MX (2) MX355849B (fr)
MY (1) MY163003A (fr)
NO (1) NO2017054I1 (fr)
NZ (1) NZ597666A (fr)
PL (1) PL2464382T3 (fr)
PT (1) PT2464382T (fr)
RS (1) RS56146B1 (fr)
SG (1) SG178324A1 (fr)
SI (1) SI2464382T1 (fr)
SM (1) SMT201700329T1 (fr)
TW (1) TWI409079B (fr)
UA (1) UA110096C2 (fr)
WO (1) WO2011018224A1 (fr)
ZA (1) ZA201200830B (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1692182E (pt) 2003-11-05 2010-05-13 Roche Glycart Ag Anticorpos de cd20 com uma afinidade de ligação acrescida ao receptor fc e uma função efectora acrescida
ATE543835T1 (de) 2007-07-16 2012-02-15 Genentech Inc Anti-cd79b-antikörper und immunkonjugate und anwendungsverfahren
ES2528922T3 (es) 2007-07-16 2015-02-13 Genentech, Inc. Anticuerpos anti-CD79b humanizados e inmunoconjugados y métodos de uso
PT2247620T (pt) 2008-01-31 2016-08-23 Genentech Inc Anticorpos e imunoconjugados anti-cd79b e métodos de utilização
MX2012013622A (es) 2010-05-31 2013-02-01 Ono Pharmaceutical Co Derivado de purinona.
FR2976811A1 (fr) * 2011-06-22 2012-12-28 Lfb Biotechnologies Utilisation d'un anticorps anti-cd20 a haute adcc pour le traitement de la maladie de waldenstrom
KR102117202B1 (ko) * 2011-08-16 2020-06-01 모르포시스 아게 항ｃｄ19 항체 및 퓨린 유사체를 이용한 병용 요법
EP2744515B1 (fr) * 2011-08-16 2022-02-09 MorphoSys AG Thérapie combinée d'un anticorps anti-cd19 avec un moutarde azotée
FR2980110A1 (fr) * 2011-09-20 2013-03-22 Lfb Biotechnologies Combinaison d'anticorps anti-cd20 et de bendamustine
DK2786996T3 (en) 2011-11-29 2016-12-19 Ono Pharmaceutical Co Hydrochloride PURINONDERIVAT
CN103375132A (zh) * 2012-04-24 2013-10-30 长江大学 井下旋转冲击式钻井工具
US9963513B2 (en) 2013-02-05 2018-05-08 Engmab Sàrl Method for the selection of antibodies against BCMA
EP2762496A1 (fr) 2013-02-05 2014-08-06 EngMab AG Procédé pour la sélection d'anticorps contre BCMA
BR112015030457A2 (pt) * 2013-06-07 2017-08-22 Nordic Nanovector As Método para regular positivamente a expressão de antígeno
JP6528779B2 (ja) 2014-03-25 2019-06-12 小野薬品工業株式会社 びまん性大細胞型ｂ細胞リンパ腫の予防および／または治療剤
DK3262071T3 (da) 2014-09-23 2020-06-15 Hoffmann La Roche Fremgangsmåde til anvendelse af anti-CD79b-immunkonjugater
JP6750613B2 (ja) 2015-04-09 2020-09-02 小野薬品工業株式会社 プリノン誘導体の製造方法
AU2016302881B2 (en) 2015-08-03 2022-09-15 Bristol-Myers Squibb Company Monoclonal antibodies against BCMA
EP3257866A1 (fr) * 2016-06-17 2017-12-20 Academisch Medisch Centrum Anticorps anti-tnf modifiés et leur utilisation dans le traitement de la maladie intestinale inflammatoire
EP3535295A1 (fr) 2016-11-02 2019-09-11 EngMab Sàrl Anticorps bispécifique contre bcma et cd3 et médicament immunologique pour une utilisation combinée dans le traitement du myélome multiple
EP3551034A1 (fr) 2016-12-07 2019-10-16 Progenity, Inc. Méthodes, dispositifs et systèmes de détection pour le tractus gastro-intestinal
EP3600416B1 (fr) 2017-03-30 2023-06-07 Biora Therapeutics, Inc. Traitement d'une maladie du tractus gastro-intestinal avec un agent immunomodulateur libéré à l'aide d'un dispositif ingérable
BR112020023704A2 (pt) 2018-05-23 2021-02-17 Celgene Corporation compostos antiproliferativos e anticorpo bispecífico contra bcma e cd3 para uso combinado
WO2019246312A1 (fr) 2018-06-20 2019-12-26 Progenity, Inc. Traitement d'une maladie du tractus gastro-intestinal avec un immunomodulateur
US12227565B2 (en) 2018-06-20 2025-02-18 Biora Therapeutics, Inc. Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
WO2020106757A1 (fr) 2018-11-19 2020-05-28 Progenity, Inc. Dispositif ingérable pour administrer un agent thérapeutique au tube digestif
JP7287048B2 (ja) 2019-03-27 2023-06-06 セイコーエプソン株式会社 ロボット
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
EP4433506A1 (fr) 2021-11-16 2024-09-25 Genentech, Inc. Méthodes et compositions pour le traitement du lupus érythémateux disséminé (sle) par mosunetuzumab

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US6750334B1 (en) 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
AU3657899A (en) 1998-04-20 1999-11-08 James E. Bailey Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
WO1999060023A1 (fr) 1998-05-15 1999-11-25 Imclone Systems Incorporated Traitement de tumeurs humaines a l'aide d'un rayonnement et d'inhibiteurs de tyrosine kinases de recepteurs du facteur de croissance
PT1176195E (pt) 1999-04-09 2013-07-18 Kyowa Hakko Kirin Co Ltd Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
KR100988949B1 (ko) 2001-10-25 2010-10-20 제넨테크, 인크. 당단백질 조성물
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
KR20110017020A (ko) 2002-10-17 2011-02-18 젠맵 에이/에스 Ｃｄ20에 대한 인간 모노클로날 항체
EP1944320A1 (fr) 2002-12-16 2008-07-16 Genentech, Inc. Variantes de l'immunoglobuline et leurs utilisations
CZ308720B6 (cs) 2003-01-22 2021-03-24 Roche Glycart Ag Fúzní konstrukty a jejich použití pro přípravu protilátek se zvýšenou vazebnou afinitou k receptorům Fc a efektorovou funkcí
JP2006528697A (ja) * 2003-05-16 2006-12-21 イデラ ファーマシューティカルズ インコーポレイテッド イムノマーを化学療法剤と組み合わせて用いる、癌の相乗的処置
EP1648511A1 (fr) 2003-07-29 2006-04-26 Morphotek, Inc. Anticorps et procedes permettant de produire des anticorps genetiquement modifies presentant une fonction effectrice amelioree
CN1871259A (zh) 2003-08-22 2006-11-29 比奥根艾迪克Ma公司 具有改变的效应物功能的经改进的抗体和制备它的方法
AU2004273791A1 (en) 2003-09-05 2005-03-31 Genentech, Inc. Antibodies with altered effector functions
PT1692182E (pt) 2003-11-05 2010-05-13 Roche Glycart Ag Anticorpos de cd20 com uma afinidade de ligação acrescida ao receptor fc e uma função efectora acrescida
WO2005103081A2 (fr) 2004-04-20 2005-11-03 Genmab A/S Anticorps monoclonaux humains diriges contre cd20
WO2007024249A2 (fr) 2004-11-10 2007-03-01 Macrogenics, Inc. Fonction effectrice obtenue par creation par genie biologique de regions d'anticorps fc
US8008443B2 (en) 2005-04-26 2011-08-30 Medimmune, Llc Modulation of antibody effector function by hinge domain engineering
CA2605697A1 (fr) 2005-04-26 2006-11-02 Bioren, Inc. Procede de production d'anticorps igg humains a fonctions effectrices renforcees
RU2482132C2 (ru) 2005-08-26 2013-05-20 Роше Гликарт Аг Модифицированные антигенсвязывающие молекулы с измененной клеточной сигнальной активностью
ES2417147T3 (es) * 2005-10-21 2013-08-06 Revo Biologics, Inc. Anticuerpos con actividad de citotoxicidad celular dependiente de anticuerpos mejorada, métodos para su producción y uso
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
US20090110688A1 (en) * 2007-10-24 2009-04-30 Georg Fertig Combination therapy of type ii anti-cd20 antibody with a proteasome inhibitor
EP2234641B1 (fr) * 2008-01-03 2015-08-19 Genmab A/S Anticorps monoclonaux anti-cd32b
EA201170940A1 (ru) * 2009-01-16 2012-02-28 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Лечение рака с использованием комбинации бендамустина и анти-cd20-антитела
WO2010120288A1 (fr) * 2009-04-15 2010-10-21 Invista Technologies S.A R.L. Procédé d'amélioration de la miscibilité de composés par ailleurs non miscibles

Also Published As

Publication number Publication date
WO2011018224A1 (fr) 2011-02-17
CR20120036A (es) 2012-04-18
IL217753A0 (en) 2012-03-29
HK1245145A1 (zh) 2018-08-24
ZA201200830B (en) 2012-10-31
CA2769674A1 (fr) 2011-02-17
CY2017034I1 (el) 2018-02-14
EP2464382B1 (fr) 2017-05-03
JP2013501740A (ja) 2013-01-17
KR101425736B1 (ko) 2014-08-01
HUS1700041I1 (hu) 2017-11-28
JP5963013B2 (ja) 2016-08-03
AR077866A1 (es) 2011-09-28
JP2016222673A (ja) 2016-12-28
US20140044705A1 (en) 2014-02-13
UA110096C2 (uk) 2015-11-25
CN107261138A (zh) 2017-10-20
AU2010281866B2 (en) 2016-05-12
RS56146B1 (sr) 2017-11-30
HRP20170972T1 (hr) 2017-09-22
MX355849B (es) 2018-05-02
US20160166688A9 (en) 2016-06-16
BR112012002855A2 (pt) 2016-11-01
SG178324A1 (en) 2012-03-29
JP2015071611A (ja) 2015-04-16
DK2464382T3 (en) 2017-07-17
NO2017054I1 (no) 2017-10-26
MX2012001782A (es) 2012-04-19
MA33469B1 (fr) 2012-07-03
CN102596245A (zh) 2012-07-18
PL2464382T3 (pl) 2017-09-29
CY1119251T1 (el) 2018-02-14
RU2012109445A (ru) 2013-09-27
EP2464382A1 (fr) 2012-06-20
NZ597666A (en) 2013-10-25
TW201110980A (en) 2011-04-01
US20120315268A1 (en) 2012-12-13
CA2769674C (fr) 2018-01-23
MY163003A (en) 2017-07-31
HUE033531T2 (hu) 2021-12-28
TWI409079B (zh) 2013-09-21
JP5646626B2 (ja) 2014-12-24
SI2464382T1 (sl) 2017-08-31
ES2630158T3 (es) 2017-08-18
US20110165151A1 (en) 2011-07-07
SMT201700329T1 (it) 2017-09-07
LT2464382T (lt) 2017-07-25
PT2464382T (pt) 2017-06-30
CY2017034I2 (el) 2018-02-14
IL217753A (en) 2016-10-31
AU2010281866A1 (en) 2012-02-02
KR20120054068A (ko) 2012-05-29
HUS000498I2 (hu) 2021-03-29
US20150093376A1 (en) 2015-04-02
LUC00045I1 (fr) 2017-11-03
CL2012000391A1 (es) 2012-08-24
LTPA2017035I1 (lt) 2017-11-27

Similar Documents

Publication Publication Date Title
BE2015C040I2 (fr)
BRPI0925311A2 (fr)
BR112012008195A2 (fr)
BR112012003062A2 (fr)
BRPI0924307A2 (fr)
BR112012008267A2 (fr)
BR112012012396A2 (fr)
BR112012000607A2 (fr)
BR122021004633A2 (fr)
BR112012000665A2 (fr)
BR112012003080A2 (fr)
BR112012012487A2 (fr)
BR112012003853A2 (fr)
BR112012009797A2 (fr)
BR112012009446A2 (fr)
BR112012009703A2 (fr)
BR112012010357A2 (fr)
BR112012001263A2 (fr)
BR112012000159A2 (fr)
BR112012014856A2 (fr)
BR112012007654A2 (fr)
BR112012005951A2 (fr)
BR112012007672A2 (fr)
BR112012000156A2 (fr)
BR112012007671A2 (fr)